anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To produce a moisture-stable solid valproic acid preparation that contains valproic acid, a filler, tablet-decomposing substance, binder and lubricant, is solid and stable to moisture without protective coating, and can be formed to tablets with a tabletting machine. CONSTITUTION: This moisture-stable solid valproic acid preparation comprises 55-65wt.% of valproic acid, 10-25wt.% of a filler (e.g. magnesium oxide), 10-20wt.% of tablet-degrading substance (e.g. corn starch), 3-6wt.% of a binder (e.g. a combination of polyvinyl pyrrolidone and sodium carboxymethlyl cellulose), and 0.5-1.2wt.% of a lubricant (e.g. magnesium stearate). By this formulation valproic acid can be prepared in the form of dry and nonhygroscopic powder which is suitable for tabletting and capsulizing without needing special package or protective treatment for maintaining its stability against moisture.
<P>PROBLEM TO BE SOLVED: To provide a method and a composition for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and a method for improving a subject's bone structure.  <P>SOLUTION: The method comprises a process for culturing the stromal cells from the adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of the cells into osteoblasts. The method and the composition like this are useful for producing the osteoblasts for autologous transplantation into a bone at a surgical site or injury. This composition comprises adipose stromal cells, a medium able to support the growth of fibroblasts and sufficient amounts of β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate or both of them to induce the differentiation of the stromal cells into osteoblasts. Further, a method for identifying compounds affecting the differentiation of osteoblasts is provided. The compound is useful in the study of bone generation and treatment of bone disorders including bone fractures and osteoporosis.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Provided is an anti-TNF-α antibody comprising a sequence modification that inhibits presentation of the antibody by human leukocyte antigen (HLA) molecules. The anti-TNF-α antibody may be infliximab or a fragment or variant thereof. In this case, the modification is suitably one that inhibits presentation of the antibody by DRB1*03:01, such as a modification in the region corresponding to residues 1 to 21 of SEQ ID NO: 1, or a modification in the region corresponding to residues 145 to 159 of SEQ ID NO: 1. Alternatively, the anti-TNF-α antibody may be adalimumab or a fragment or variant thereof. In this case, the modification may be one that inhibits presentation of the antibody by DQA1*05:05/DQB1*03:01. Also provided are nucleic acid sequences that encode an antibody according to the invention, and pharmaceutical composition comprising an antibody or nucleic acid sequence of the invention. The antibodies and pharmaceutical compositions of the invention may be of use in the treatment of autoimmune diseases, or disorders selected from the group consisting of: Crohn's disease; ulcerative colitis; rheumatoid arthritis; psoriatic arthritis; psoriasis; ankylosing spondylitis; and Behçet's disease.
In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
The pathogenesis of myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) double-expressor diffuse large B-cell lymphoma (DE-DLBCL) remains unclear. To investigate how MYC and BCL2 contribute to tumor aggressiveness, we analyzed tumors from 14 patients each with DE-DLBCL and non-DE-DLBCL using whole transcriptome sequencing. Validation was performed using publicly available data sets, tumor tissues from 126 patients, DLBCL cell lines, and a syngeneic mouse lymphoma model. Our transcriptome analysis revealed significantly elevated messenger RNA levels of C-C motif chemokine ligand 2 (CCL2) and C-C chemokine receptor type 2 (CCR2) in DE-DLBCLs when compared with non-DE-DLBCLs (adjusted P value < .05). Transcriptomic analysis of public data sets and immunohistochemistry corroborated these findings, indicating increased levels of M2 macrophages but a reduction in T-cell infiltration in DE-DLBCLs when compared with non-DE-DLBCLs (all P < .05). CCR2 expression was observed mainly in tumor-infiltrating macrophages and not in DLBCL cells. Increased expression of CCL2 and CCR2 was significantly associated with a poor prognosis in patients with DLBCL. In the in vitro analyses, MYChigh/BCL2high DLBCL cells showed higher CCL2 expression and secretion than MYClow/BCL2low cells. MYC and BCL2 increased CCL2 expression and secretion by upregulation of nuclear factor κB p65 in DLBCL cells, and CCL2 promoted M2 polarization of macrophages. In a mouse lymphoma model, CCL2 contributed to the immunosuppressive microenvironment and tumor growth of MYChigh/BCL2high tumors. We demonstrated that the increased CCL2/CCR2 axis confers aggressiveness to DE-DLBCL by increasing M2 polarization and can be a potential therapeutic target.
The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
Lithium has been used for decades to treat Bipolar Affective Disorder. Some of its therapeutic benefits are through the inhibition of the enzyme Glycogen Synthase Kinase-3 (GSK-3). GSK3 activity is associated with the development of several aspects of AD and thus lithium can regulate an enzyme linked to AD development. As an important step towards designing a clinical trial to investigate the potential of lithium for AD prevention the investigators propose to establish the minimum dose of lithium needed to block GSK3 in people with Mild Cognitive Impairment (MCI), a high-risk condition for progression to AD. The study will establish whether GSK3 activity is altered in MCI and monitor lithium regulation of GSK3 biomarkers in this population. At the same time the study will investigate how GSK3 measured in blood relates to GSK3 activity in the brain in a small animal study. In further preparation for a future large scale trial, this pilot study will generate technical data to develop the technique of using Magnetic Resonance Spectroscopy (MRS) as a biomarker to detect the earliest brain changes of AD.

Recruitment will be shared between the two sites for this study, Dundee and Oxford. The study will involve 12 patients with MCI and 12 controls, who will be asked for two sets of blood tests, and 20 patients with MCI who consent to take Lithium who will be asked for blood tests at regular intervals. For all participants the study period is 12 weeks.
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester ( e . g ., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base ( e . g ., petroleum jelly) and/or an organic alcohol ( e . g ., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
The present invention relates to an extraction technology of effective components in Chinese medicine. In particular, the present invention relates to a novel method of using ultrasound to extract an effective component quercetin in ginkgo leaves. The method uses a design program of orthogonal experiment. Based on technical parameters of the generation method, ultrasonic intensity, functional duration, functional method, solvent type, temperature of the system, and the mixing method of ultrasound through screening and extraction process, the fresh ginkgo leaves can be prepared. The ginkgo leaves are dried at a temperature of 60 DEG C for 24 hours and crushed and screened (0.45 Mu m) to be a material. The ginkgo leaves are filled into ethanol solution of 45 percent in an ultrasonic extraction reactor; the material and solution are mixed according to a ratio (Kg: L) of 1 to from 14 to 15. The generation method of ultrasound comprises a simulated audible device of ultrasound and a radial cylindrical vibration transducer. The ultrasonic power is 100W, and the ultrasonic frequency is 28 kHz. In the extraction method, the ultrasound functions once with an interval of 5 minutes; the functional time of ultrasound is 3 minutes; the total extraction time is 32 minutes; the extraction temperature is 45 DEG C; the stirring method is an air-lift stirring way. With the methods, the extraction rate of the effective component quercetin in ginkgo leaves can reach 96.28 percent.
Chronic total occlusions (CTOs) represent the "final frontier" of coronary interventions with the lowest procedural success rates and the most common reason for incomplete revascularization and referral to coronary artery bypass graft surgery (CABG). CTO lesions are not an infrequent finding during coronary angiography. They are often responsible for enhancing the complexity of the coronary disease burden thereby affecting the final interventional decision in the process. Notwithstanding the modest technical success of CTO-PCI, most of the earlier observational data demonstrated a clear survival benefit free of major cardiovascular events (MACE) in patients undergoing successful CTO revascularization. However, data from recent randomized trials fail to uphold the same survival advantage albeit, showing some trend toward improvement in left ventricular function, quality of life indicators and freedom from fatal ventricular arrythmia. Various guidance statements propose a well-defined role for CTO intervention in specific situations provided criterions for patient selection, appreciable inducible ischemia, myocardial viability and cost-risk-benefit analysis are met.
PURPOSE: To obtain a wrinkle-smoothing agent exhibiting excellent stability and wrinkle-smoothing effect and useful as a cosmetic component and prepare a skin-beautifying cosmetic containing the smoothing agent by using a pear pip essence as an active component. CONSTITUTION: This wrinkle-smoothing agent contains the essence of pips of a pear such as Japanese pear (e.g. Chojurou, Housui, Kousui and Nijusseiki) and common pear (e.g. brandy and francaise) as active component. The essence can be prepared by pressing the pear pips or extracting the pips with an organic solvent and concentrating the extract. A skin beautifying cosmetic can be prepared by incorporating 0.1-10wt.% of the wrinkle-smoothing agent.
OBJECTIVE: Tinnitus is a multifactorial phenomenon with quality-of-life detriments for those affected by it. We aim to establish a relationship between subjective tinnitus severity with objective audiometric data in the extended high frequency (EHF) from 9 to 16 khz and with distortion product otoacoustic emissions (DPOAE). We hypothesize that severe subjective tinnitus as measured by the Tinnitus Handicap Inventory (THI) does not correlate with increased hearing thresholds in the EHF range.
STUDY DESIGN: Prospective.
SETTING: Single Tertiary Care Center.
METHODS: Patients identified with tinnitus and normal hearing thresholds within standard frequency range (250-8000 Hz) were consented for participation. Those with underlying otologic disease, trauma, radiotherapy, or ototoxic drug use were excluded. The THI questionnaire was given to eligible patients and audiometric test results were collected. THI scores were categorized by severity groups. An n = 20 to 30 was determined to have an effect size of 0.7 with a significance level of P = .05.
RESULTS: THI and audiometric data were collected for 38 patients and categorized into mild (n = 18, 47.4%), moderate (n = 8, 21.1%), slight (n = 7, 18.4%), and severe (n = 5, 13.2%) tinnitus severity groups. Mean THI score was 32.3 ± 19.6 with a statistically significant difference in scores by assigned THI severity group (P < .01). There were no significant differences or linear relationship among hearing thresholds in EHF range or DPOAE stratified by subjective tinnitus group (P = .49, r2 = 0.10) CONCLUSION: Subjective tinnitus severity is not predictive of audiometric outcomes. This finding can be used as a counseling tool to help tinnitus patients manage symptoms, expectations, and overall treatment outcomes.
Plasma amyloid beta (Aβ) and tau are emerging as accessible biomarkers for Alzheimer's disease (AD). However, many assays exist with variable test performances, highlighting the need for a comparative assessment to identify the most valid assays for future use in AD and to apply to other settings in which the same biomarkers may be useful, namely, cerebral amyloid angiopathy (CAA). CAA is a progressive cerebrovascular disease characterized by deposition of Aβ40 and Aβ42 in cortical and leptomeningeal vessels. Novel immunotherapies for AD can induce amyloid-related imaging abnormalities resembling CAA-related inflammation. Few studies have evaluated plasma biomarkers in CAA. Identifying a CAA signature could facilitate diagnosis, prognosis, and a safer selection of patients with AD for emerging immunotherapies. This review evaluates studies that compare the diagnostic test performance of plasma biomarker techniques in AD and cerebrovascular and plasma biomarker profiles of CAA; it also discusses novel hypotheses and future avenues for plasma biomarker research in CAA.
Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
Exceeding the recommended dose in patients with good renal function or administering the usual dose to patients with impaired renal function (common in elderly patients) may lead to increased serum levels and toxic reactions. Methemoglobinemia generally follows a massive, acute overdose. Methylene blue, 1 to 2 mg/kg/body weight intravenously or ascorbic acid 100 to 200 mg given orally should cause prompt reduction of the methemoglobinemia and disappearance of the cyanosis which is an aid in diagnosis. Oxidative Heinz body hemolytic anemia may also occur, and “bite cells” (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to hemolysis. Renal and hepatic impairment and occasional failure, usually due to hypersensitivity, may also occur.
<P>PROBLEM TO BE SOLVED: To simultaneously provide the advantage that cases similar to an image to be diagnosed can be viewed and the advantage that images different in imaging modalities can be interpreted for increased reliability of diagnosis.  <P>SOLUTION: The input of a plurality of images from different imaging modalities representing the same subject is received. Features are calculated on the plurality of images. Features are also acquired for images having the same imaging modalities as the plurality of images out of images constituting case image sets stored in a case database each including a plurality of images different in imaging modalities representing a subject of the same kind as the subject. The features on the plurality of images are compared with the features on the case image sets, and overall similarities are calculated. A predetermined number of image sets are retrieved from the case database and output as search results in descending order of overall similarity.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Immune checkpoint inhibitors have opened an era of lung cancer therapy. However, a notable disparity exists in the efficacy of immunotherapy among individual patients. The tertiary lymphoid structure (TLS) is an ectopic lymphocyte aggregation that appears under pathological conditions and is the primary site of action for anti-tumor immunity. It is commonly reported that the presence of TLS within the tumor microenvironment (TME) relates to a favorable clinical prognosis and an excellent response to immunotherapy in lung cancer patients. A thorough understanding of TLS and its dynamic changes in TME has become an attractive focus for optimizing immunotherapy strategies for lung cancer. In this review, we comprehensively generalize the composition, formation, mechanism, detection methods of TLS, and summarize the role of TLS in lung cancer immunotherapy. Finally, induction of TLS is also discussed, which may provide more effective therapeutic strategies for lung cancer therapy.
The invention discloses a mucin-philin Acremonium (Akkermansia muciniphila), which has a preservation number of CGMCC No.23185. The invention also discloses application of the mucin-philin ackermannin bacterium in preparing a medicament for preventing and/or treating pancreatic tumors. The invention also discloses a composition which comprises the akkermansia muciniphila as an active ingredient. The invention also discloses application of the akkermansia muciniphila in preparing a pharmaceutical composition for enhancing the efficacy of an anti-tumor drug. The invention also discloses a culture or a processed product thereof containing the akkermansia muciniphila. The mucin-philin Acremonium provided by the invention has better growth and proliferation capability, can secrete more key immunoregulatory substances such as palmitoleic acid, can inhibit the number of CD8+T cells more effectively so as to inhibit the growth of pancreatic tumor cells, and can also obviously increase the concentration of chemotherapeutic drugs in the pancreatic tumor microenvironment, thereby enhancing the efficacy of antitumor drugs.
Orthostatic hypotension, falls, and syncope have been reported in patients treated with the recommended Duloxetine delayed-release capsules dosages. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during Duloxetine delayed-release capsules treatment, particularly after dose increases. The risk of falling appears to be related to the degree of orthostatic decrease in blood pressure (BP) as well as other factors that may increase the underlying risk of falls.

In an analysis of patients from all placebo-controlled trials, patients treated with duloxetine reported a higher rate of falls compared to patients treated with placebo. Risk appears to be related to the presence of orthostatic decrease in BP. The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Warnings and Precautions (5.12) and Drug Interactions (7.1)] and in patients taking duloxetine at doses above 60 mg daily. Consideration should be given to dose reduction or discontinuation of Duloxetine delayed-release capsules in patients who experience symptomatic orthostatic hypotension, falls and/or syncope during duloxetine therapy.

Risk of falling also appeared to be proportional to a patient's underlying risk for falls and appeared to increase steadily with age. As geriatric patients tend to have a higher underlying risk for falls due to a higher prevalence of risk factors such as use of multiple medications, medical comorbidities and gait disturbances, the impact of increasing age by itself is unclear. Falls with serious consequences including fractures and hospitalizations have been reported with duloxetine use [see Adverse Reactions (6.1)].
A method and system for providing a terminally sterilized transdermal device adapted to delivery a parathyroid hormone-based agent. A microprojection member that includes a plurality of stratum corneum-piercing microprojections is coated with PTH-based agent formulation an exposed to sufficient radiation to sterilize the microprojection member while retaining sufficient activity of the PTH-based agent. Preferably, the microprojection member is sealed in packing with an inert atmosphere and reduced moisture. The sterilizing radiation can be gamma radiation or e-beam, preferably delivered in a dose in the range of approximately 5 - 50 kGy. Also preferably, the irradiation is performed at -78.5-25°C. In preferred embodiments, the radiation is delivered at a rate greater than 3.0 kGy/hr.
BACKGROUND: Patients with Takotsubo syndrome (TTS) who develop cardiogenic shock may present with left ventricular outflow tract obstruction (LVOTO). The prognosis and treatment of this population have not been defined in previous studies. The aim of this study is to describe the clinical presentation, management, evolution and prognosis of a subgroup of patients with TTS and cardiogenic shock according to whether they present with LVOTO or not.
METHODS: We analysed patients with TTS recruited from 2003 to 2022 in a multicentre registry. Patients were selected if they presented cardiogenic shock during their admission. This analysis was compared according to the presence or absence of LVOTO.
RESULTS: 322 patients were included, 58 (18%) of whom had LVOTO. The majority were treated with vasoactive and inotropic therapy (VIT) and its use was strongly associated with having LVOTO (77.6% vs 57.6%, p<0.001). Only five (3.3%) patients without LVOTO and two (4.4%) in the LVOTO group treated with VIT developed or worsened the obstruction. Furthermore, patients with LVOTO presented higher in-hospital complications including ventricular arrhythmias (15.5% vs 8.7%, p=0.017), major bleeding (13.8% vs 6.1%, p=0.042) and acute kidney failure (48.3% vs 28.4%, p=0.003). However, at both 90 days and 5 years, the cumulative incidence of all-cause death was not significantly different between the patients with and without LVOTO (HR 1.20, 95% CI 0.60 to 2.40 for 90 days, and HR 1.69, 95% CI 0.89 to 3.21 for 5 years).
CONCLUSIONS: LVOTO is not uncommon in patients with TTS and cardiogenic shock. It is associated with a more aggressive in-hospital course and our data is unable to rule out an association between the presence of LVOTO and long-term prognosis of patients with TTS. The development or worsening of LVOTO directly related to inotropic or vasoactive support was low.